
IndraLab
Statements
Hydroxychloroquine inhibits cytokine production. 39 / 39
|
18
21
eidos
"Both CQ and HCQ accumulate in lysosomes , destabilizing lysosomal membranes , altering lysosomal and endosomal pH , and interfering with lysosomal activity and autophagosome function.6 Both compounds may furthermore reduce antigen presentation , inhibit cytokine production ( interleukin [ IL ] -1 , interferon [ IFNalpha ] , and tumor necrosis factor [ TNF ] ) , and affect Toll-like receptor signaling and cyclic guanosine monophosphate-adenosine monophosphate [ GMP-AMP ] synthase activity ."
reach
"Immunomodulatory effects of chloroquine as well as hydroxychloroquine include inhibition of antigen presentation to dendritic cells, reduced cytokine production in macrophages and reduced signaling of both B and T cells.Therefore, in addition to direct antiviral effects, chloroquine and hydroxychloroquine may play a role in reducing the cytokine storm associated with COVID-19 progression to ARDS."
eidos
"During the early months of the COVID-19 pandemic , hydroxychloroquine , a medication commonly used to prevent malaria infection and treat autoimmune diseases , gained global attention for its effectiveness in treating COVID-19 in vitro.6-11 Hydroxychloroquine is found to reduce the entry of coronavirus into a cell through interference with the terminal glycosylation of the angiotensin-converting enzyme 2 ( ACE2 ) receptor , which inhibits viral replication.6 8 Additionally , hydroxychloroquine has immunomodulatory activity , and may inhibit cytokine production and prevent the occurrence of cytokine storm.12 Early studies examining the treatment of COVID-19 with hydroxychloroquine showed mixed results with some studies showing no average benefit in outcomes , including intubation or inpatient mortality , but other studies showing worse outcomes.13-22 A recent randomised clinical trial study examining the effects of hydroxychloroquine found no difference in clinical outcomes between patients treated with and without hydroxychloroquine ."
eidos
"Hydroxychloroquine can reduce the inflammatory response and cytokine storm ( aggressive inflammatory response with the release of a large amount of pro-inflammatory cytokines ) in patients severely infected with SARS-CoV-2 by blocking T-cell stimulation , and thus decreasing cytokine production ."
| PMC
eidos
"During the early months of the COVID-19 pandemic , hydroxychloroquine , a medication commonly used to prevent malaria infection and treat autoimmune diseases , gained global attention for its effectiveness in treating COVID-19 in vitro.6-11 Hydroxychloroquine is found to reduce the entry of coronavirus into a cell through interference with the terminal glycosylation of the angiotensin-converting enzyme 2 ( ACE2 ) receptor , which inhibits viral replication.6 8 Additionally , hydroxychloroquine has immunomodulatory activity , and may inhibit cytokine production and prevent the occurrence of cytokine storm.12 Early studies examining the treatment of COVID-19 with hydroxychloroquine showed mixed results with some studies showing no average benefit in outcomes , including intubation or inpatient mortality , but other studies showing worse outcomes.13-22 A recent randomised clinical trial study examining the effects of hydroxychloroquine found no difference in clinical outcomes between patients treated with and without hydroxychloroquine.23 ."
reach
"As previous research identified a significant increase in macrophage numbers in endometriosis induced mice 22 and that HCQ can inhibit cytokine production in human macrophages, 23 we therefore assessed macrophage numbers in control, recipient (untreated), PBS treated, and HCQ treated recipient mice."
eidos
"Both CQ and HCQ accumulate in lysosomes , destabilizing lysosomal membranes , altering lysosomal and endosomal pH , and interfering with lysosomal activity and autophagosome function.6 Both compounds may furthermore reduce antigen presentation , inhibit cytokine production ( IL-1 , IFNalpha , TNF ) , and affect in Toll-like receptor signalling and cyclic GMP-AMP ( cGAMP ) synthase ( cGAS ) activity ."